- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Camurus AB (CAMX)
Camurus AB stock price live, this page displays ST CAMX stock exchange data. View the CAMX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Camurus AB real time stock price chart below.
What Is the Camurus AB Stock Price Today?
The Camurus AB stock price today is 670,00.
What Is the Stock Symbol for Camurus AB?
The stock symbol for Camurus AB is "CAMX."
What Stock Exchange Does Camurus AB Trade On?
Camurus AB is listed and trades on the Stockholm stock exchange.
Is Camurus AB a Good Stock to Buy?
Determining whether Camurus AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CAMX quote. (ISIN: SE0007692850)
What Is the Camurus AB Stock Price Today?
The Camurus AB stock price today is 670,00.
What Is the Stock Symbol for Camurus AB?
The stock symbol for Camurus AB is "CAMX."
What Stock Exchange Does Camurus AB Trade On?
Camurus AB is listed and trades on the Stockholm stock exchange.
Is Camurus AB a Good Stock to Buy?
Determining whether Camurus AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CAMX quote. (ISIN: SE0007692850)
670.00
+6.00(+0.90%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
655.00
670.00
52 wk Range
430.80
710.00
Earnings results expected in 15 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
655.00670.00
52 wk Range
430.80710.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CAMX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
807.25
Upside
+20.49%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 807.25
(+20.49% Upside)
Camurus AB Earnings Call Summary for Q2/2026
- Camurus reported Q2 2026 revenue of SEK 702M (+4% YoY, +32% QoQ) with EPS of SEK 4.05, beating estimates by 26.6%; shares surged 17% to $616.5.
- Record product sales of SEK 528M driven by Buvidal (SEK 524M) and BRIXADI royalties (SEK 127M, +42% YoY); operating margin reached 42% at SEK 293M.
- Company maintains SEK 4.1B cash position with zero debt; reaffirmed full-year 2026 guidance despite June FDA Complete Response Letter for Oclaiz.
- Oclaiz CRL attributed to third-party manufacturing issues, not efficacy/safety; remediation complete with 2026 resubmission expected pending FDA inspection.
- Key catalysts include Q4 2026 SORENTO GEP-NET results for CAM2029, H2 2026 phase IIb start for CAM2056, and SEK 350M allocated for commercial/R&D expansion.
Last Updated: 2026/07/15, 14:48
Read Full TranscriptEarnings
Latest Release
Jul 15, 2026
EPS / Forecast
4,07 / 3,23
Revenue / Forecast
702M / 627,83M
Compare CAMX to Peers and Sector
Metrics to compare | CAMX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCAMXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 59.7x | 72.9x | −0.3x | |
PEG Ratio | −9.45 | 0.08 | 0.00 | |
Price/Book | 8.7x | 2.5x | 2.6x | |
Price / LTM Sales | 17.9x | 4.4x | 2.9x | |
Upside (Analyst Target) | 21.6% | 231.8% | 64.0% | |
Fair Value Upside | Unlock | 6.8% | 7.8% | Unlock |
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hypertension, as well as in phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; NewBridge Pharmaceuticals; and Eli Lilly for the development of long-acting incretin medicines based on FluidCrystal technology. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Camurus AB (CAMX) Stock Price Today?
The Camurus AB stock price today is 670,00 SEK.
What Stock Exchange Does Camurus AB Trade On?
Camurus AB is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for Camurus AB?
The stock symbol for Camurus AB is "CAMX."
What Is the Camurus AB Market Cap?
As of today, Camurus AB market cap is 39,51B SEK.
What Is Camurus AB's Earnings Per Share (TTM)?
The Camurus AB EPS (TTM) is 11,37.
When Is the Next Camurus AB Earnings Date?
Camurus AB will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is CAMX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Camurus AB Stock Split?
Camurus AB has split 1 times.
How Many Employees Does Camurus AB Have?
Camurus AB has 316 employees.
What is the current trading status of Camurus AB (CAMX)?
As of Oct 21, 2026, Camurus AB (CAMX) is trading at a price of 670,00 SEK, with a previous close of 664,00 SEK. The stock has fluctuated within a day range of 655,00 SEK to 670,00 SEK, while its 52-week range spans from 430,80 SEK to 710,00 SEK.
What Is Camurus AB (CAMX) Price Target According to Analysts?
The average 12-month price target for Camurus AB is 807,25 SEK, with a high estimate of 950 SEK and a low estimate of 650 SEK. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +20,49% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.